A diagnostics company has agreed to stop selling two questionable blood tests as part of a settlement with a consumer watchdog that accused the firm of using “false and misleading advertising” to promote the products.
Not only was EpicGenetics claiming that one of its blood tests could definitively diagnose fibromyalgia, the Center for Science in the Public Interest’s October 2023 lawsuit said; the company had also invented a disease wholesale to justify the use of another product, and had dangled nonexistent treatment trials as an enticement for patients.
EpicGenetics, its founder and CEO Bruce Gillis, and his other companies continue to deny all wrongdoing, but they have agreed to stop marketing and selling those two tests, to limit the claims they make about other products, and to pay $158,000 of CSPI’s legal fees, according to the settlement, which went into effect on July 30.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
